Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Cancer, treatment tamoxifen

Droloxifene (3-hydroxy-tamoxifen) behaves as an estrogen agonist in bone tissue and several lipid and coagulation markers in castrated rat models and does not show stimulation of the endometrial epithelium in preclinical studies (Ke et al. 1997). Endometrial stimulation has, however, been observed in clinical trials, which, together with the fact that as an estrogen agonist it is ten times less potent than tamoxifen in bone tissue and lipid metabolism (Hendrix et al. 2001) and that in a recent head-to-head comparison with tamoxifen droloxifene was demonstrated not to be superior in any parameter of breast cancer treatment efficacy (Buzdar et al. 2002), has resulted in cancellation of its clinical development. [Pg.68]

The main potential utility of the pure antiestrogens is in the treatment of breast cancer. Several studies on their effects on the breast demonstrate both the pure antiestrogenic action of the tested compounds and their beneficial effects on breast cancer treatment. In experiments conducted in nude mice xenotrans-planted with two different human estradiol-dependent breast tumors, a single injection of fulvestrant provided an antitumor efficacy equivalent to that of daily tamoxifen treatment for at least 4 weeks (Wakeling et al. 1991). Additionally, RU 58668 was able to induce up to 30% disappearance of MCF-7 breast... [Pg.158]

Jin, Y., Desta, Z., Stearns, V., et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 97, 30-39. [Pg.72]

Another application of this chemistry is the asymmetric synthesis of the cyclopropane analog 25 of the breast cancer treatment agent tamoxifen 26 (Scheme 14.2) [53]. The Rh2(S-DOSP)4-catalyzed reaction of phenyldiazoacetate 3 with diarylethylene 23 at... [Pg.308]

The successful response of breast cancers to tamoxifen or progestin treatment depends on the presence of high-affinity receptors for estrogen, progesterone, or both. Fewer than 10% of mammary tumors that lack detectable ER levels will respond to hormonal therapies. Determination of hormone receptor levels in tumor samples is highly recommended before selecting a therapy. [Pg.711]

Nguyen, A., Marsaud, V., Bouclier, C., Top, S., Vessieres, A., Pigeon, R, Gref, E., Legrand, R, Jaouen, G., and Renoir, J. M. 2008. Nanoparticles loaded with ferrocenyl tamoxifen derivatives for breast cancer treatment. Int. J. Pharmaceut. 347 128-35. [Pg.163]

Wiseman H. Tamoxifen Molecular Basis of use in Cancer Treatment and Prevention, John Wiley, Chichester, 1994. [Pg.390]

When assessing the risk of endometrial malignancy in women with breast cancer taking tamoxifen, it is worth taking into account evidence that patients with breast cancer may at the outset have some endometrial pathology. In women with breast cancer scheduled for tamoxifen there were endometrial polyps in 9.3%, endometrial cysts in 16%, and synechiae in 12% at the outset. Tamoxifen significantly increased the incidence of these benign endometrial lesions, usually after less than 1 year of treatment. There were no cases of endometrial carcinoma in 34 patients who had taken tamoxifen for 12-24 months, and only one in 78 patients who had taken it for 5-72 months (103). [Pg.308]

Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80 61-74... [Pg.139]

Borges S et al (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80 61-74... [Pg.239]

Schroth W et al (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25 5187-5193... [Pg.247]

Ramon y Cajal T et al (2010) Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat 119 33-38... [Pg.247]

One of the most widely used treatments for breast cancer uses tamoxifen (Figure 14.8). It was originally developed as a contraceptive, but it was found that it inhibited oestrogen uptake by cells. Tamoxifen alters the shape of a protein on the surface of the oestrogen receptor and so stops it from giving the signal to grow . [Pg.211]

Tamoxifen is a nonsteroid competitive oestrogen antagonist on target organs. Although available for anovulatory infertility (20 mg daily on days 2, 3, 4 and 5 of the cycle) its main use now is in the treatment of oestrogen-dependent breast cancer. Treatment with tamoxifen delays the growth of metastases and increases survival if tolerated it should be continued for 5 years. [Pg.719]

Zoledronic acid has also been investigated in the prevention of cancer treatment-induced bone loss in 401 premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer in a randomised, open-label. Phase 111 clinical trial [76]. In this study, patients received tamoxifen and goserelin with or without zoledronic acid (4 mg i.v. every 6 months) versus anastrozole and goserelin with or without zoledronic acid (4 mg i.v. every 6 months) for 3 years. The combination of zoledronic acid with endocrine therapy was well tolerated and was not associated with changes in renal function in this patient population. Over 3 years, 2, 904 serum creatinine measurements were taken, the mean serum creatinine level was 0.78 + 0.17 mg/ dl, and no patient had serum creahnine levels that exceeded 1.5 times the upper limit of normal [76]. [Pg.556]

Idoxifene has been evaluated as a breast cancer treatment for postmenopausal patients [296, 297]. In one study, 321 postmenopausal patients with unknown receptor status or hormone receptor-positive metastatic breast cancer were randomized to receive either tamoxifen or idoxifene as first-line endocrine therapy for their advanced disease. Complete plus partial response rates were 9 and 13% for tamoxifen and idoxifene, respectively. The median time to progression was slightly higher for idoxifene (140 versus 166 days), but these differences were not statistically significant. Morbidity was similar for both groups. The authors concluded that in postmenopausal women with metastatic breast cancer idoxifene had similar efficacy and toxicity to tamoxifen [298]. However, idoxifene has not been developed further because of concerns about uterine prolapse [299]. This side-effect is not seen with tamoxifen. [Pg.153]

Senkus-Konefka, E., Konefka, T. and Jassem, J. (2004) The effects of tamoxifen on the female genital tract. Cancer Treatment Reviews, 30, 291—301. [Pg.180]

BREAST CANCER Tamoxifen is highly efficacious in the palliation of advanced breast cancer in women with ER-positive tumors and for hormonal treatment of both early and advanced breast cancer in women of aU ages. Response rates are -50% in women with ER-positive tumors and 70% for ER-positive, PR-positive tumors. Tamoxifen increases disease-free and overall survival a 5-year treatment period is more efficacious than shorter treatments. Tamoxifen reduces by 50% the risk of developing contralateral breast cancer in women at high risk and is approved for primary prevention in this setting. Prophylactic treatment should be hmited to 5 years. The most frequent side effect is hot flashes. Tamoxifen increases the risk of endometrial cancer and thromboembolic disease by two- to threefold. [Pg.1003]


See other pages where Cancer, treatment tamoxifen is mentioned: [Pg.221]    [Pg.64]    [Pg.101]    [Pg.280]    [Pg.299]    [Pg.313]    [Pg.51]    [Pg.52]    [Pg.52]    [Pg.713]    [Pg.713]    [Pg.315]    [Pg.221]    [Pg.3300]    [Pg.3654]    [Pg.781]    [Pg.783]    [Pg.1066]    [Pg.77]    [Pg.80]    [Pg.797]    [Pg.2354]    [Pg.2358]    [Pg.141]    [Pg.182]   
See also in sourсe #XX -- [ Pg.6 , Pg.295 , Pg.296 , Pg.297 , Pg.302 , Pg.314 ]




SEARCH



Breast cancer, treatment tamoxifen

Cancer treatment

Tamoxifen

Tamoxifene

© 2024 chempedia.info